Cargando…

Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?

Detalles Bibliográficos
Autores principales:	Oh, Gyu Man, Moon, Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385576/ https://www.ncbi.nlm.nih.gov/pubmed/32713169 http://dx.doi.org/10.5217/ir.2020.00061

Ejemplares similares

Patients treated with a tumor necrosis factor-α inhibitor are more likely to develop extrapulmonary tuberculosis
por: Lee, Sang-Oh
Publicado: (2013)

Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy
por: Phan, Hiep, et al.
Publicado: (2020)

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
por: Kawaguchi, Takumi, et al.
Publicado: (2022)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
por: Kucharz, Eugeniusz Józef, et al.
Publicado: (2021)

Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients
por: Kang, Eunjung, et al.
Publicado: (2016)

Tumor necrosis factor‐α inhibitor‐induced follicular psoriasiform eruption
por: Goldberger, Tal, et al.
Publicado: (2022)

Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis
por: Hagino, Teppei, et al.
Publicado: (2023)

Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
por: Jeong, Hyemin, et al.
Publicado: (2018)

Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
por: Desai, Rishi J., et al.
Publicado: (2014)

Tumor necrosis factor: is it time to change the name?
por: Pisetsky, David S
Publicado: (2014)

Tumor necrosis factor receptor I, II and tumor necrosis factor-α levels in patients with burns
por: Endo, S, et al.
Publicado: (2000)

Polymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammation
por: Washburn, Newell R., et al.
Publicado: (2013)

Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy
por: Bielewicz-Zielińska, Agnieszka, et al.
Publicado: (2015)

Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment
por: Takazono, Takahiro, et al.
Publicado: (2016)

Acquired epidermodysplasia verruciformis in setting of tumor necrosis factor-α inhibitor therapy
por: Schultz, Brittney, et al.
Publicado: (2018)

Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors
por: Muth, Katharina N., et al.
Publicado: (2023)

Paradoxical effects of tumour necrosis factor-α in adjuvant-induced arthritis
por: Williams, Richard O
Publicado: (2008)

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
por: Kang, Eun Ae, et al.
Publicado: (2022)

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Predicting the future of anti-tumor necrosis factor therapy
por: Verweij, Cornelis L
Publicado: (2009)

Protective effect of etanercept, an inhibitor of tumor necrosis factor-α, in a rat model of retinal ischemia
por: Bae, Hyoung Won, et al.
Publicado: (2016)

Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms
por: JAMMAL, MILLENA PRATA, et al.
Publicado: (2015)

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies
por: Huyghe, Leander, et al.
Publicado: (2020)

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa
por: Soto Lopes, Marien Siqueira, et al.
Publicado: (2013)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
por: Jang, Dan-in, et al.
Publicado: (2021)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis
por: Kwon, Oh Chan, et al.
Publicado: (2022)

Tumor necrosis factor inhibitors – state of knowledge
por: Lis, Krzysztof, et al.
Publicado: (2014)

Bacteriologically Determined De Novo Tuberculosis during Tumor Necrosis Factor-α Inhibitor Therapy
por: Takahashi, Gen, et al.
Publicado: (2019)

Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
por: Chung, Keun Bum, et al.
Publicado: (2013)

Factors Associated with Elevated Tumor Necrosis Factor-α in Aqueous Humor of Patients with Open-Angle Glaucoma
por: Jung, Younhea, et al.
Publicado: (2022)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Salivary tumor necrosis factor-α and periodontal destruction
por: Tin, Sim Sai, et al.
Publicado: (2015)

Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology
por: Salomon, Benoît L., et al.
Publicado: (2018)

Tumor necrosis factor α Inhibition for Alzheimer’s Disease
por: Chang, Rudy, et al.
Publicado: (2017)

Tumor Necrosis Factor-α: The Next Marker of Stroke
por: Xue, Yimeng, et al.
Publicado: (2022)

Patients’ Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus Western
por: Seo, Hyungil, et al.
Publicado: (2016)

Erratum: Correction of Notes. Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

In vivo Anti‐tumor Efficacy of Polyethylene Glycol‐modified Tumor Necrosis Factor‐α against Tumor Necrosis Factor‐resistant Tumors
por: Tsutsumi, Yasuo, et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_kgl6mnu99k3jb6m6q9vjhe7bfs